Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
NCT02556801Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Sep 2015
- Primary completion
- Oct 2016
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of phleum pratense extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Sep 2015; status: completed.
02
Drugs
phleum pratense extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02556801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556801.